Anafranil, 25 mg 30 pcs.

Anafranil is a tricyclic antidepressant, an inhibitor of norepinephrine and serotonin reuptake.

Anafranil acts on the depressive syndrome in general, including especially on such its typical manifestations as psychomotor retardation, depressed mood and anxiety. Clinical effect is usually observed after 2-3 weeks of treatment.

In addition, Anafranil has a specific (different from its antidepressant effect) effect in obsessive-compulsive disorders.

The action of Anafranil in chronic pain syndromes, whether or not due to somatic diseases, is probably due to the facilitation of nerve impulse transmission mediated by serotonin and noradrenaline.

Indications

Adults treatment of depressive states of various etiologies, occurring with different symptoms: endogenous, reactive, neurotic, organic, masked, involutional forms of depression; depression in patients with schizophrenia and psychopathy; depressive syndromes that occur in old age, caused by chronic pain syndrome or chronic somatic diseases; depressive mood disorders of a reactive, neurotic or psychopathic nature; obsessive-compulsive syndromes; chronic pain syndrome; phobias and panic attacks; cataplexy accompanying narcolepsy.

Pharmacological effect

Anafranil is a tricyclic antidepressant, a norepinephrine and serotonin reuptake inhibitor.

Anafranil acts on depressive syndrome in general, incl. especially on such typical manifestations as psychomotor retardation, depressed mood and anxiety. The clinical effect is usually observed after 2-3 weeks of treatment.

In addition, Anafranil has a specific (different from its antidepressant effect) effect in obsessive-compulsive disorders.

The effect of Anafranil in chronic pain syndromes, both caused and not caused by somatic diseases, is probably associated with the facilitation of nerve impulse transmission mediated by serotonin and norepinephrine.

Special instructions

Before starting treatment with Anafranil, hypokalemia must be eliminated.

Active ingredient

Clomipramine

Composition

1 tablet contains clomipramine hydrochloride 25 mg

Pregnancy

Experience with the use of Anafranil during pregnancy is limited. Since there are isolated reports of a possible connection between the use of tricyclic antidepressants and fetal developmental disorders, the use of Anafranil during pregnancy should be avoided, unless the expected effect of treatment on the mother clearly outweighs the potential risk to the fetus.

Contraindications

– hypersensitivity to clomipramine and other components of the drug, cross-hypersensitivity to tricyclic antidepressants from the dibenzazepine group;
– simultaneous use of MAO inhibitors, as well as a period of less than 14 days before and after their use;
– simultaneous use of selective MAO type A inhibitors of reversible action (such as moclobemide);
– recent myocardial infarction;
— congenital long QT syndrome;
– pregnancy and lactation.

Side Effects

Side effects of Anafranil are most often mild and somewhat similar to symptoms of depression. As a rule, effects of this kind disappear during treatment or after reducing and reaching the minimum active dosage. If the adverse reactions are serious and threaten the patient’s life, the medication should be stopped.

Interaction

With the combined use of ethanol and drugs that depress the central nervous system (including other antidepressants, barbiturates, benzodiazepines and general anesthetics), a significant increase in the inhibitory effect on the central nervous system, respiratory depression and hypotensive effect is possible. Increases sensitivity to drinks containing ethanol.

Overdose

The symptoms that develop with an overdose of Anafranil are similar to those described with an overdose of other tricyclic antidepressants.

Storage conditions

In a dry place

Shelf life

5 years

Manufacturer

Novartis Pharma S.p.A., Italy